Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study (EXCEED)

Caen University Hospital

Status: Completed

Conditions: Multiple Sclerosis

Treatments: Biological: glutamate and aspartate

Study type: Interventional

Funder types: Other

Identifiers

NCT02523703

06-063

Details and patient eligibility

About

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. In France, thanks to recent studies reported during general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy, the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year.

The primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.

Enrollment: 36 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Man or woman between 18 and 60 years old.
• Patient with one or more type of inflammatory events of Central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive myelitis)
• No treatment with corticosteroids for less than 1 month
• Need for a lumbar puncture performed in the etiologic
• Need a brain MRI performed within the etiologic
• Patient who signed informed consent

Exclusion criteria

• Secondary progressive MS
• Any cons-indication for lumbar puncture
• Any contra-indication to MRI
• Minor patient or patient major under guardianship

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

36 participants in 2 patient groups

Healthy Volunteers

Other group

Description:

Healthy Volunteers

Treatment:

Biological: glutamate and aspartate

Multiple Sclerosis patient

Other group

Description:

Multiple Sclerosis patient

Treatment:

Biological: glutamate and aspartate